I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Enalapril is a ACE (angiotensin-converting enzyme) inhibitor, suggested to be more potent than Captopril (sc-200566). Studies indicate that Enalapril downregulates the expression of IL-β, IL-6, and NF-κB. Further studies show that Enalapril upregulates the expression of VEGF and heme oxygenase-1. Enalaprilat reports demonstrate that the compound has some antioxidant activity, which does not include the PKC-NADPH oxidase pathway.
P. Ahlin.; J. Kristl.; A. Kristl; F. Vrečer. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration.Int. J. Pharm. 2002, 239 (1-2),113-120 .
Peter W Swaan.; Marco C Stehouwer.; Josef J Tukker. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril.Biochimica et Biophysica Acta (BBA) - Biomembranes. 1995, 1236 (1),31-38 .